Navigation Links
MATH, HPV status in HNSCC patients effective markers of improved patient outcome
Date:2/20/2014

Scottsdale, Ariz., February 20, 2014Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

The TCGA data available for HNSCC patients included 302 patients, with 35 HPV-positive patients. The researchers' examination confirmed that high tumor MATH at time of surgery is an indicator of poor outcome (high-MATH hazard ratio (HR) = 2.1; 95 percent confidence interval (CI), 1.4 to 3.2; p = 0.0002, logrank test) and that HPV-positive HNSCC patients have lower average MATH values than HPV-negative HNSCC patients. In bivariate analysis, both MATH and HPV were significantly associated with survival. When stratified by HPV status, MATH was similarly related to outcome in clinically defined subsets of patients regardless of clinical characteristics (tumor margins, nodal classification or tumor staging). Median follow-up with the 173 surviving patients was 22 months.

A tumor can contain many different types of cancer cells. Standard DNA sequencing discovers both the DNA mutations that differ among cancer cells and gives a measure of diversity. Genetic heterogeneity of each tumor was assessed by MATH, the percentage ratio of the width to the center of the distribution of tumor-specific mutant-allele fractions. In order to compare to previous studies, analysis was limited to mutant-allele fractions no less than 0.075, and the high-MATH cutoff value of 32, previously found to distinguish outcome classes, was used. Cox proportional hazards analysis was used to evaluate the relations of MATH and HPV to overall survival.

"Calculating patients' MATH marker as well as their HPV status is a more reliable predictor of patient survival, and the methodology that we used to measure MATH is simple enough that it could be adopted readily in the clinic,"said author James Rocco, MD, PhD, a head and neck surgical oncologist at Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, and the Daniel Miller Chair in Otology and Laryngology at Harvard Medical School in Boston. "Now that we know that both HPV status and intra-tumor heterogeneity matter for patient outcome, we are in a better position to personalize therapy for our patients. We can try less toxic therapies in patients likely to be cured, and try new or alternate therapies in patients likely to fail. In addition, it may help identify the patients most likely to benefit from clinical trials."


'/>"/>
Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Kessler Foundation MS researchers study predictors of employment status
2. Vitamin D status associated with multiple sclerosis activity, progression
3. Pradaxa Lawsuits Move Forward, as Federal Litigation Schedules January Status Conference, Bernstein Liebhard LLP Reports
4. Federal GranuFlo Lawsuits Move Forward with Scheduling of First Status Conference of the New Year, Bernstein Liebhard LLP Reports
5. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
6. Tylenol Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Tylenol Litigation
7. Give an Hour Provides Mental Health Services, at No Cost, to Members of the Military and Veterans of Iraq and Afghanistan Regardless of Discharge Status
8. Atlanta-Based Agency Force Marketing Achieves Google Partner Status
9. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on November Status Conference in Federal Pradaxa Bleeding Litigation
10. New links between social status and brain activity
11. Actos Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Actos Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
Breaking Medicine Technology: